|
Dr. Capetola has over 25 years of experience in the pharmaceutical and biotechnology industry, managing teams that developed several important drugs to commercialization, including erythropoietin, Retin-A, Suprol, Floxin, Suprane, oral contraceptives, inhaled nitric oxide and Revex. Dr. Capetola was employed for 17 years at Johnson & Johnson, starting as a drug discovery scientist and rising to the position of Senior Worldwide Director of Experimental Therapeutics. After Johnson & Johnson, Dr. Capetola joined Ohmeda Pharmaceuticals, a division of the BOC Group, as Vice President of Research and Development, while also serving as the President and Board Director of Delta Biotechnology, a UK subsidiary of Ohmeda. In late 1996, Dr. Capetola founded Acute Therapeutics, Inc., a company focused on humanized lung surfactant technology, acquired via an exclusive sub-license from Johnson & Johnson. One year later, Dr. Capetola merged his company with Discovery Laboratories, and began to focus the business on developing precision-engineered surfactants for a wide array of respiratory indications. Dr. Capetola received his B.S. from the Philadelphia College of Pharmacy & Science and his Ph.D. in Pharmacology from Hahnemann Medical College. | 